STOK Stoke Therapeutics, Inc.
$26.23▲ +0.38%
Healthcare
Other
Volume 307.5K
Avg Volume (10D) 1.51M
Key Metrics & Fundamentals
Market Cap
$1.69B
P/E Ratio
–
Div Yield
0.00%
52W Range
20.32 - 40.22
% vs 50 MA
-5.94%
% vs 200 MA
-15.65%
RSI-14
51.6
MACD Histogram
+0.3800
Beta (1Y vs SPY)
0.79
Free Cash Flow
-$58.56M
Gross Rev
$9.33M
Gross Profit
$9.33M
EBITDA
-$64.97M
COGS
–
Operating Exp
$74.75M
Operating Income
-$65.43M
EBIT
-$65.43M
Pretax Income
-$61.62M
Net Income
-$61.62M
EPS (Diluted)
-0.93
Price & Volume History
Loading chart…
Recent News
Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight
PR Newswire · Oct 27, 2026 10:31 AM ET
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates
Business Wire · Oct 22, 2026 8:00 AM ET
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Business Wire · Oct 16, 2026 4:20 PM ET
Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
Business Wire · Oct 12, 2026 8:00 AM ET
FDA Alignment on Zorevunersen Endpoints Could Be A Game Changer For Stoke Therapeutics (STOK)
Simply Wall St. · Oct 9, 2026 7:09 PM ET
Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
Business Wire · Oct 6, 2026 8:00 AM ET
Stoke Therapeutics Completes FDA Meeting on Planned Zorevunersen NDA
MT Newswires · Oct 5, 2026 8:13 AM ET
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Business Wire · Oct 5, 2026 7:00 AM ET
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
Business Wire · Sep 23, 2026 4:01 PM ET
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Business Wire · Sep 16, 2026 4:01 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See STOK's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.